Table 2.
Neurological manifestations and mortality.
| Manifestations | Frequency | Gender | Age | SAH | MD2 | VMA | Dead | Dead | p-value |
|---|---|---|---|---|---|---|---|---|---|
| with NM | w/out NM | BLR | |||||||
| Cephalea | 86 | M (53) F (33) | 58 (16) | 47 | 37 | 36 | 34 | 106 | 0.71 |
| Neurological impairment | 44 | M (26) F (18) | 65 (17) | 25 | 19 | 34 | 33 | 107 | <0.001 |
| Anosmia | 23 | M (16) F (7) | 52 (17) | 4 | 9 | 9 | 9 | 131 | 0.70 |
| Ageusia | 20 | M (13) F (7) | 55 (19) | 3 | 8 | 8 | 8 | 132 | 0.60 |
| CVE | 13 | M (8) F (5) | 73 (8) | 10 | 8 | 7 | 7 | 133 | 0.17 |
| Delirium | 9 | M (5) F (4) | 63 (15) | 6 | 5 | 5 | 3 | 137 | 0.97 |
| Convulsive crises | 7 | M (5) F (2) | 38 (21) | 3 | 3 | 2 | 2 | 138 | 0.37 |
| Vascular dementia | 5 | M (3) F (2) | 74 (16) | 3 | 3 | 3 | 3 | 137 | 0.30 |
| Parkinson's disease | 3 | M (2) F (1) | 77 (12) | 2 | 2 | 2 | 2 | 138 | 0.75 |
| Panhypopituitarism | 2 | M (2) F (0) | 43 (22) | 2 | 0 | 2 | 0 | – | – |
| Epileptic status | 1 | M (1) F (0) | 29 | 0 | 0 | 0 | 0 | – | – |
| Tumors | 1 | M (1) F (0) | 62 | 1 | 0 | 1 | 1 | – | – |
| Cerebral palsy | 1 | M (1) F (0) | 51 | 0 | 0 | 1 | 1 | – | – |
| Meningoencephalitis | 1 | M (0) F (1) | 18 | 0 | 0 | 1 | 1 | – | – |
| Myelomeningocele | 1 | M (0) F (1) | 29 | 0 | 0 | 1 | 1 | – | – |
| Myasthenia gravis | 1 | M (0) F (1) | 65 | 0 | 0 | 0 | 0 | – | – |
| Multiple sclerosis | 1 | M (0) F (1) | 18 | 0 | 0 | 1 | 1 | – | – |
| Encephalopathy | 1 | M (0) F (1) | 64 | 0 | 0 | 0 | 0 | – | – |
SAH = systemic arterial hypertension, MD2 = Mellitus Diabetes 2, VMA = Ventilatory Mechanical Assistance, NM = neurological manifestations, = mean, SD = standard deviation, χ2 = Chi-squared, BLR = binary logistic regression.